Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study

BACKGROUND: Viral rebound after nirmatrelvir–ritonavir treatment has implications for the clinical management and isolation of patients with COVID-19. We evaluated an unselected, population-wide cohort to identify the incidence of viral burden rebound and associated risk factors and clinical outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Carlos K H, Lau, Kristy T K, Au, Ivan C H, Lau, Eric H Y, Poon, Leo L M, Hung, Ivan F N, Cowling, Benjamin J, Leung, Gabriel M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949892/
https://www.ncbi.nlm.nih.gov/pubmed/36796397
http://dx.doi.org/10.1016/S1473-3099(22)00873-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949892/
https://www.ncbi.nlm.nih.gov/pubmed/36796397
http://dx.doi.org/10.1016/S1473-3099(22)00873-8

Ejemplares similares